HCID 67125885、化合物 → HCID 54761863、化合物
反応式
Cl.[C:2]([C:6]1[O:10][N:9]=[C:8]([NH:11][C:12](=[O:36])[N:13]([C:15]2[CH:20]=[CH:19][C:18]([NH:21][C:22](=[O:35])[C:23]3[CH:28]=[CH:27][C:26]([O:29][CH:30]4[CH2:34][CH2:33][NH:32][CH2:31]4)=[CH:25][N:24]=3)=[CH:17][CH:16]=2)[CH3:14])[CH:7]=1)([CH3:5])([CH3:4])[CH3:3].Cl.F[CH2:39][C:40](C1ON=C(NC(=O)NC2C=CC(NC(=O)C3C=CC(OC4CCNCC4)=CN=3)=CC=2)C=1)(C)[CH2:41]F>>[C:2]([C:6]1[O:10][N:9]=[C:8]([NH:11][C:12](=[O:36])[N:13]([C:15]2[CH:16]=[CH:17][C:18]([NH:21][C:22](=[O:35])[C:23]3[CH:28]=[CH:27][C:26]([O:29][CH:30]4[CH2:34][CH2:33][N:32]([CH:40]([CH3:41])[CH3:39])[CH2:31]4)=[CH:25][N:24]=3)=[CH:19][CH:20]=2)[CH3:14])[CH:7]=1)([CH3:5])([CH3:3])[CH3:4]参加物
3
実験手順
N-(4-(3-(5-tert-Butylisoxazol-3-yl)-1-methylureido)phenyl)-5-(1-isopropylpyrrolidin-3-yloxy)picolinamide (45 mg, 68%) was prepared using a procedure analogous to that described in Example 20, substituting N-(4-(3-(5-tert-butylisoxazol-3-yl)-1-methylureido)phenyl)-5-(pyrrolidin-3-yloxy)picolinamide hydrochloride from the Step 2 of this example for N-(4-(3-(5-(1,3-difluoro-2-methylpropan-2-yl)isoxazol-3-yl)ureido)phenyl)-5-(piperidin-4-yloxy)picolinamide hydrochloride used in Example 20. LC-MS (ESI) m/z 521 (M+H)+.
出典と根拠
- ORDレコード
- ord-99c93fc6125f47acaace45ae118c1638
- 出典データセット
- uspto-grants-2016_03
- DOI